Full-Time

Senior Manager

PharmSci Clinical Manufacturing Planning

Takeda

Takeda

10,001+ employees

Global biopharmaceutical firm; R&D-driven NMEs

Compensation Overview

$137k - $215.3k/yr

+ Short-term incentives + Long-term incentives + 401(k) match

Lexington, MA, USA

In Person

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Six Sigma
GMP
Google Cloud Platform

Get referred to Takeda

See people who can refer or advise you

Requirements
  • A bachelor's degree in Life Sciences, Engineering, Supply Chain, Operations, Pharmacy, Business, or another scientific or technical discipline is required.
  • Demonstrated experience developing and managing production plans, supply scenarios, inventory strategies, or demand/supply balancing processes in a regulated environment.
  • Strong working knowledge of drug substance and drug product planning principles, including how manufacturing constraints, demand changes, inventory posture, and lead times affect supply continuity.
  • Experience applying scenario modeling and risk-based planning approaches to evaluate alternatives, identify constraints, and support cross-functional decision-making.
  • Sound knowledge of GxP requirements and the ability to incorporate GMP, GDP, and GCP considerations into planning outputs, communications, and escalation decisions.
  • Strong analytical and quantitative skills, including the ability to synthesize data, identify trends, and generate actionable planning recommendations.
  • Demonstrated ability to influence cross-functional stakeholders and align teams around assumptions, recommendations, and execution priorities.
  • Strong communication and presentation skills, with the ability to prepare clear, concise, and decision-ready planning materials for governance and leadership review.
  • Proven ability to manage multiple projects of moderate complexity simultaneously while maintaining high-quality outputs and meeting timelines.
  • Demonstrated track record of improving planning processes, tools, templates, or ways of working within a function or team setting.
Responsibilities
  • Develop and maintain integrated drug substance and drug product production plans for assigned programs or assets, ensuring plans are feasible, risk-managed, and aligned with program requirements and manufacturing constraints.
  • Translate demand signals, technical inputs, and network constraints into decision-ready production plans, scenarios, and inventory strategies.
  • Lead development of alternative planning scenarios to evaluate timing, capacity, inventory, and cost tradeoffs under changing conditions.
  • Identify, quantify, and communicate supply risks and mitigation strategies, and incorporate agreed actions into planning outputs.
  • Align cross-functional stakeholders, including CMC, contract development and manufacturing organization managers, and GCSC planners, on planning assumptions, recommended actions, and execution priorities.
  • Prepare governance, escalation, and decision-support materials for planning reviews and portfolio discussions.
  • Monitor execution against plan, assess changes in program or manufacturing conditions, and adjust plans proactively to maintain supply continuity.
  • Drive adoption of standardized planning practices and contribute to continuous improvement of planning processes, tools, and governance frameworks.
Desired Qualifications
  • 6+ years of relevant experience in pharmaceutical, biotech, clinical manufacturing, supply chain planning, CMC, or contract manufacturing environments.
  • An advanced degree is preferred.
  • Certifications such as APICS/CPIM/CSCP, PMP, Lean, or Six Sigma are preferred but not required.

Takeda is a global biopharmaceutical company focused on discovering and delivering medicines and vaccines to improve patient health. It relies on extensive research and development to create new molecular entities (NMEs) and bring them to market, aiming for up to 15 product launches through FY2024 from a pipeline of 11 NMEs. Revenue comes mainly from selling pharmaceutical products, supported by about 41,000 third-party suppliers worldwide. The company differentiates itself through a deep history (over 240 years), a broad portfolio of global brands, and a patient-centric approach that places patients’ needs at the center of its operations while pursuing environmental sustainability. Takeda’s goal is to advance health globally by turning scientific innovations into accessible therapies, maintaining long-term growth through steady product innovation and responsible operations.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Get referred to Takeda

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Orzeyful launch opens a new neurology franchise with disease-modifying pricing power.
  • Takeda’s Q1 fiscal 2026 revenue rose 10.2% reported, driven by new launches.
  • Boltz partnership gives Takeda organization-wide AI access for structure prediction and generative design.

What critics are saying

  • Boston jurors found Takeda liable on May 18, 2026; appeal runs through 2026.
  • Takeda booked roughly 403.5 billion yen for Amitiza exposure, crushing fiscal 2025 profit.
  • Takeda will cut about 4,500 jobs in fiscal 2026, signaling integration strain after Shire.

What makes Takeda unique

  • Takeda’s Orzeyful became the first FDA-approved orexin therapy on August 5, 2026.
  • Takeda already won China approval for Orzeyful in July 2026, extending first-mover advantage.
  • Takeda’s dengue vaccine is India’s first approved Japanese dengue vaccine, strengthening emerging-market positioning.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 5th, 2026
FDA approves Takeda's Orzeyful, first medicine to treat underlying cause of narcolepsy type 1

The US Food and Drug Administration has approved Takeda's ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first orexin receptor 2 agonist approved to address the underlying cause of the disease rather than individual symptoms. Narcolepsy type 1 is a chronic neurological disease affecting approximately 120,000 people in the US. It is driven by orexin deficiency and causes excessive daytime sleepiness, cataplexy, cognitive symptoms and disrupted sleep. Clinical trials showed adults taking ORZEYFUL experienced significant improvements across the full range of symptoms compared to placebo. Takeda is preparing for the US launch, which will proceed following completion of the Drug Enforcement Administration scheduling process. The company describes the approval as potentially redefining how narcolepsy type 1 is managed.

GeekWire
Jul 31st, 2026
AI drug developer Accipiter Bio quietly tops up seed round with $10.5M

Seattle-based biotech startup Accipiter Biosciences has raised an additional $10.5 million, less than a year after emerging from stealth with $12.7 million. The funding, from existing investors including Flying Fish Partners and Takeda, will accelerate the company's drug development programmes. The startup uses AI tools developed at the University of Washington's Institute for Protein Design to engineer proteins that can bind multiple cellular targets simultaneously. The company has expanded to 22 employees, including researchers who worked under Nobel laureate David Baker. Accipiter Bio has partnerships with Pfizer and Gilead Sciences-owned Kite Pharma, with potential milestone payments exceeding $330 million. The additional funding will enable the company to advance three or four drug candidates into clinical trials, focusing on immunology and oncology.

Yahoo Finance
Jul 30th, 2026
Takeda Pharmaceutical Q1 results on track as new launches offset mature product declines

Takeda Pharmaceutical reported first-quarter fiscal 2026 results aligned with its full-year outlook. Revenue totalled JPY 1.22 trillion, up 10.2% on an actual foreign-exchange basis but down 0.5% at constant exchange rates. Core operating profit reached JPY 358.9 billion, rising 11.5% on an actual FX basis. The company's core inline brands, representing 58% of total revenue, grew 2.3% at constant exchange rates. New launches accounted for 4% of revenue but grew 22.6%, supported by FRUZAQLA, LIVTENCITY, ADZYNMA and QDENGA. Takeda is preparing three product launches: ORZEYFUL for narcolepsy type 1, rusfertide for polycythemia vera, and zasocitinib for psoriasis. The company maintained its fiscal 2026 guidance and expects to generate JPY 650 billion to JPY 750 billion in free cash flow.

Nikkei Asia
Jul 21st, 2026
India approves first dengue vaccine from Japan's Takeda

India has approved Takeda Pharmaceutical's dengue vaccine, marking the country's first approved vaccine for the disease. The Japanese drugmaker received regulatory approval as authorities seek to combat dengue's accelerating transmission across India. Dengue, a mosquito-borne viral infection, poses a significant public health challenge in tropical regions. The approval represents a milestone in India's efforts to address the disease burden. The vaccine's introduction comes as dengue cases continue to rise in the country, making prevention efforts increasingly urgent for Indian health authorities.

Business Wire
Jun 24th, 2026
Julie Kim becomes Takeda's president and CEO as pharmaceutical giant prepares three major launches

Takeda has appointed Julie Kim as Representative Director, President and CEO, completing an 18-month transition. Shareholders elected Kim as an internal director during the company's 150th Annual General Meeting in Osaka, after which the Board appointed her to the top role. Former president and CEO Christophe Weber retired following the meeting. Kim joined Takeda in 2019 through the Shire acquisition and previously held roles including president of the Plasma-Derived Therapies Business Unit and president of the U.S. Business Unit. She brings over three decades of global healthcare experience. Shareholders also elected three new external directors: Bruce Broussard, Koichiro Kimura and Dr Paul Stoffels. Takeda's Board now comprises 11 members, with eight serving as external directors. The company plans three major launches over the next 12 months.